Skip to main content
Clinical Trials/NCT04424745
NCT04424745
Completed
Not Applicable

A Feasibility Study of Transcranial Direct Current Stimulation with Attention Bias Modification Training for Binge Eating Disorder

King's College London1 site in 1 country84 target enrollmentFebruary 25, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Binge-Eating Disorder
Sponsor
King's College London
Enrollment
84
Locations
1
Primary Endpoint
Achievement of a 'steady state' of recruitment
Status
Completed
Last Updated
last year

Overview

Brief Summary

Binge eating disorder (BED) is a common and disabling eating disorder (ED) which has significant effects on psychological wellbeing, physical health, and quality of life. Talking therapies, most notably cognitive behaviour therapy (CBT), are presently recommended for the treatment of BED. However, outcomes from treatment are inadequate. Therefore, there is a need for development of new treatments.

This study aims to investigate the feasibility of combining Attention Bias Modification Training (ABMT) and Transcranial Direct Current Stimulation (tDCS) to reduce binge-eating behaviour and craving for food in people with BED.

ABMT is a computerised training that seeks to alter responses towards food that people are not consciously aware of. During ABMT, participants are trained to 'look towards' low-calorie food and 'look away' from high-calorie food. TDCS is a safe, well tolerated, non-invasive form of brain stimulation which is suitable for supervised self-administration. It stimulates specific brain areas using a mild electrical current (2 mA) via small electrodes placed on the scalp. In this study, participants will be randomly allocated to receive either ABMT with real tDCS or ABMT with sham tDCS. ABMT and real/sham tDCS will be delivered simultaneously, i.e. participants will engage in ABM training whilst receiving tDCS. All participants will be remotely supervised by the study researcher for the duration of each treatment session.

Biological male and female adults (aged 18-60) of any gender will be eligible to take part if they have a DSM-V of BED and they are overweight or obese.

Taking part will involve completing 10 sessions of combined ABMT and real or sham tDCS over 2-3 weeks. Binge frequency, food craving and other outcomes will be measured at the start of the study, end of the study, and at the 6-week follow-up.

Registry
clinicaltrials.gov
Start Date
February 25, 2021
End Date
September 30, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Overweight or obese according to WHO criteria (BMI\>25 kg/m²)
  • Meet criteria for full-syndrome DSM-5 Binge Eating Disorder (BED)
  • Right-handed
  • Must use and understand English as a language for everyday conversation
  • Access to a laptop or desktop computer with webcam

Exclusion Criteria

  • Visual impairments that cannot be corrected with contact lenses or glasses
  • Pregnancy
  • History of neurological disease and/or seizure
  • Having any metallic implants anywhere in the head or body
  • History of head or eye injury
  • Significant health problems in the previous six months
  • Lifetime diagnosis of substance dependence, psychosis, bipolar disorder, borderline personality disorder
  • Other primary psychiatric disorder requiring treatment in its own right
  • Taking psychotropic medication other than a stable dosage of selective serotonin reuptake inhibitors (SSRI) for at least 14 days prior to study enrollment
  • Adults consuming more than 14 units of alcohol per week who are unwilling to reduce their alcohol intake for the duration of the treatment.

Outcomes

Primary Outcomes

Achievement of a 'steady state' of recruitment

Time Frame: Start of Recruitment to 12 months

Recruitment rate/month over months will be assessed to demonstrate that recruitment targets for the main trial can be met within an adequate time-frame. An average of 3 patients per month must be recruited (randomised) over a consecutive 12 month period (a minimum of 36 patients) in order to demonstrate a 'steady state' of recruitment.

Secondary Outcomes

  • Eating Disorder Symptoms(Baseline to 6 week follow up (on average, 8 weeks after baseline assessment))
  • Attention Bias for Food(Baseline to 6 week follow up (on average, 8 weeks after baseline assessment))
  • Craving for food(Baseline to 6 week follow up (on average, 8 weeks after baseline assessment))
  • General psychopathology(Baseline to 6 week follow up (on average, 8 weeks after baseline assessment))
  • Food related attention(Baseline to 6 week follow up (on average, 8 weeks after baseline assessment))
  • Physical Health(Baseline to 6 week follow up (on average, 8 weeks after baseline assessment))
  • Working Memory(Baseline to post treatment (on average 18 days after baseline assessment))
  • Face Affective Go/No Go(Baseline to post treatment (on average 18 days after baseline assessment))
  • Cognitive Flexibility(Baseline to post treatment (on average 18 days after baseline assessment))

Study Sites (1)

Loading locations...

Similar Trials